Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H18N3S.Cl.3H2O |
Molecular Weight | 373.898 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.[Cl-].CN(C)C1=CC2=[S+]C3=CC(=CC=C3N=C2C=C1)N(C)C
InChI
InChIKey=XQAXGZLFSSPBMK-UHFFFAOYSA-M
InChI=1S/C16H18N3S.ClH.3H2O/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;;;;/h5-10H,1-4H3;1H;3*1H2/q+1;;;;/p-1
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C16H18N3S |
Molecular Weight | 284.399 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/monograph/methylene-blue.htmlCurator's Comment: http://www.mdpoison.com/media/SOP/mdpoisoncom/healthcareprofessionals/antidote-facts/Methylene%20Blue%20Antidote%20Facts.pdf |
https://clinicaltrials.gov/ct2/show/NCT01797978 | https://www.pharmgkb.org/pathway/PA165980834
Sources: https://www.drugs.com/monograph/methylene-blue.html
Curator's Comment: http://www.mdpoison.com/media/SOP/mdpoisoncom/healthcareprofessionals/antidote-facts/Methylene%20Blue%20Antidote%20Facts.pdf |
https://clinicaltrials.gov/ct2/show/NCT01797978 | https://www.pharmgkb.org/pathway/PA165980834
Methylene blue, also known as methylthioninium chloride, is a medication from WHO's list of essential medicines. Upon administration, methylene blue is converted to leukomethylene blue by erythrocyte methemoblobin reductase in the presence of NADPH. Leukomethylene blue than reduces methemoglobin to oxyhemoglobin, thus restoring oxygen carrying capacity of the blood. Methylene blue is also used as a dye for various diagnostic procedures, for treatment of ifosfamide toxicity and for in vitro staining. Historically, it was used as a photosensitizer for photodynamic therapy for topical treatment of dermatologic or mucocutaneous infections, as an antidote for cyanide poisoning, but these applications are no longer approved. Methylene blue is investigated in clinical trials for treatment of septic shock and Alzheimer's disease.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17428524
Curator's Comment: When injected intraperitoneally into live rats, MB crosses the blood-brain barrier and selectively stains brain tissueand selectively stains brain tissue.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P00387|||Q9UL55 Gene ID: 1727.0 Gene Symbol: CYB5R3 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/7396878 |
|||
Target ID: CHEMBL2111350 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7679577 |
5.3 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | METHYLENE BLUE Approved UseUsed for methemoglobinemia associated with certain drugs (e.g., dapsone, benzocaine, lidocaine), occupational or other exposures to toxic chemicals (e.g., hydrazine, amine-substituted benzenes, nitro-substituted benzenes, nitrates, nitrites), or substance abuse (e.g., inhalation or ingestion of volatile nitrites). |
|||
Primary | METHYLENE BLUE Approved UseManagement of ifosfamide-induced encephalopathy |
|||
Diagnostic | METHYLENE BLUE Approved UseHas been used as diagnostic (visualizing) dye in a variety of procedures, including sentinel lymph node biopsy in cancer patients (e.g., breast cancer patients), endoscopic evaluation of lesions in patients with GERD or Barrett's esophagus, urologic evaluation in patients with ureteral or renal pelvis injury, and thoroscopic procedures in patients with pulmonary nodules. |
|||
Primary | METHYLENE BLUE Approved UseHas been used as a photosensitizer for photodynamic therapy for topical treatment of dermatologic or mucocutaneous infections (e.g., herpes labialis, eczema herpeticum, oral candidiasis, cutaneous leishmaniasis, chromoblastomycosis) or chronic dermatologic or mucocutaneous conditions (e.g., plaque psoriasis, oral lichen planus). |
|||
Primary | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10952480/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHYLENE BLUE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2917 ng/mL |
2 mg/kg single, intravenous dose: 2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHYLENE BLUE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
134 μM × min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10952480/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHYLENE BLUE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
13977 ng × h/mL |
2 mg/kg single, intravenous dose: 2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHYLENE BLUE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10952480/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHYLENE BLUE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
24 h |
2 mg/kg single, intravenous dose: 2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHYLENE BLUE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6% |
2 mg/kg single, intravenous dose: 2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHYLENE BLUE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
72 mg/kg 4 times / day multiple, intravenous Highest studied dose Dose: 72 mg/kg, 4 times / day Route: intravenous Route: multiple Dose: 72 mg/kg, 4 times / day Sources: |
unhealthy, 0.5-4.9 |
Other AEs: Anemia... |
1 g single, intravenous Overdose |
healthy, 3 |
Disc. AE: Tachycardia, Cyanosis... AEs leading to discontinuation/dose reduction: Tachycardia Sources: Cyanosis |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Anemia | 0.8% | 72 mg/kg 4 times / day multiple, intravenous Highest studied dose Dose: 72 mg/kg, 4 times / day Route: intravenous Route: multiple Dose: 72 mg/kg, 4 times / day Sources: |
unhealthy, 0.5-4.9 |
Cyanosis | Disc. AE | 1 g single, intravenous Overdose |
healthy, 3 |
Tachycardia | Disc. AE | 1 g single, intravenous Overdose |
healthy, 3 |
PubMed
Title | Date | PubMed |
---|---|---|
[The enhancement of formalin induced agitation behavior by intrathecal administration of prostaglandin E1]. | 1999 Aug |
|
Spinal antinociceptive effect of epidural nonsteroidal antiinflammatory drugs on nitric oxide-induced hyperalgesia in rats. | 1999 Jul |
|
Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? | 2003 Jun |
|
Methylene blue for lithium-induced refractory hypotension in off-pump coronary artery bypass graft: report of two cases. | 2004 Feb |
|
Evaluating risk factors for the development of ifosfamide encephalopathy. | 2005 Jun |
|
Dual action of phenylarsine oxide on the glucose transport activity of GLUT1. | 2009 Dec 10 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/monograph/methylene-blue.html
Main route of adminitration is intravenous, 1-2 mg/kg by slow IV injection. Inject slowly over several minutes (usually 3–10 minutes). Historically was also administered orally, but oral preparations are no longer commercially available in US. As a photosensitizer is administered topically. For a diagnostic purposes is administered by local instillation or injection.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7396878
Suspension of erytrocytes from acid/citrate/dextrose-treated blood were incubabed on air with 0.5M M-sodium nitrite solution in isoosmotic saline. The erytrocytes were separated by centrifugation, washed, and incubated at pH 7.4 and 37°C with 10 mM glucose and 10 uM Methylene Blue. Samples were taken at defined intervals and hemolysed with 10 vol of ice-cold water, after that the content of mehtemoglobin, hemoglobins intermediate and oxyhemoglobin was estimated.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:37:03 GMT 2025
by
admin
on
Mon Mar 31 17:37:03 GMT 2025
|
Record UNII |
T42P99266K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
345711
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
||
|
EPA PESTICIDE CODE |
39505
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
||
|
NCI_THESAURUS |
C461
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
||
|
FDA ORPHAN DRUG |
385512
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
||
|
FDA ORPHAN DRUG |
357111
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
METHYLENE BLUE
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
PRIMARY | |||
|
CHEMBL191083
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
PRIMARY | |||
|
T42P99266K
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
PRIMARY | |||
|
6878
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
PRIMARY | RxNorm | ||
|
122965-43-9
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
D008751
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
PRIMARY | |||
|
DTXSID0025600
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
PRIMARY | |||
|
1428008
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
PRIMARY | |||
|
6872
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
PRIMARY | |||
|
DB09241
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
PRIMARY | |||
|
7220-79-3
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
PRIMARY | |||
|
C644
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
PRIMARY | |||
|
SUB08877MIG
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
PRIMARY | |||
|
T42P99266K
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
PRIMARY | |||
|
m7402
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
PRIMARY | Merck Index | ||
|
759135
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
PRIMARY | |||
|
METHYLENE BLUE
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
PRIMARY | Other name: Methylene blue.Description: Dark green crystals with a metallic lustre or a dark green, crystalline powder; odourless or almost odourless. Solubility: Sparingly soluble in water; slightly soluble in ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Antidote. Storage: Methylthioninium chloride should be kept in a tightly closed container, protected from light. Additional information: Methylthioninium chloride is hygroscopic. Definition: Methylthioninium chloride contains not less than 97.0% and not more than 101.0% of C16H18ClN3S, calculated with reference to the dried substance. | ||
|
104827
Created by
admin on Mon Mar 31 17:37:03 GMT 2025 , Edited by admin on Mon Mar 31 17:37:03 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
||
|
ANHYDROUS->SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|